Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04253912Phase 2Unknown

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Role: lead

NCT03207906Phase 2Completed

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Role: lead

NCT03077750Phase 2Completed

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

Role: lead

NCT02483455Phase 2Completed

ALC-919 For The Treatment Of Common Warts

Role: lead

All 4 trials loaded